Skip to main content
Erschienen in: Clinical & Experimental Metastasis 5/2013

01.06.2013 | Research Paper

Value of metastin receptor immunohistochemistry in predicting metastasis after radical nephrectomy for pT1 clear cell renal cell carcinoma

verfasst von: Sunao Shoji, Mayura Nakano, Tetsuro Tomonaga, Hakushi Kim, Kazuya Hanai, Yukio Usui, Yoshihiro Nagata, Masaki Miyazawa, Haruhiro Sato, Xian Yang Tang, Yoshiyuki Robert Osamura, Toyoaki Uchida, Toshiro Terachi, Koichi Takeya

Erschienen in: Clinical & Experimental Metastasis | Ausgabe 5/2013

Einloggen, um Zugang zu erhalten

Abstract

KISS-1 is a metastasis-suppressor gene of human melanoma, and encodes metastin, which was identified as the ligand of a G-protein-coupled receptor (metastin receptor). The precursor protein is cleaved to 54 amino acids, which may be further truncated into carboxy-terminal fragments. Previous studies showed that lack of metastin receptor in clear cell renal cell carcinoma (RCC) is associated with tumor progression, but the prediction of metastasis in patients with pT1 clear cell RCC after radical nephrectomy is difficult. The objective of this study was to evaluate the usefulness of metastin receptor immunohistochemistry in predicting metastasis after nephrectomy for pT1 clear cell RCC. After verification of the correlation between immunostaining and mRNA expression, we evaluated the clinical value of metastin receptor immunohistochemistry. Fifty-four patients were enrolled in this study; following radical nephrectomy, seven patients were found to have lung metastasis. The sensitivity, specificity, positive predictive value, and negative predictive value with negative immunostaining of metastin receptor were 85.7, 97.6, 46.2, and 97.6 %, respectively. Metastasis-free survival rates were significantly higher in patients with positive staining (97.6 %) than in patients with negative staining (53.8 %) (P < 0.001). In univariate analysis for metastasis-free survival, negative immunostaining of metastin receptor was a significant risk factor for metastasis (P = 0.001). Furthermore, negative immunostaining of metastin receptor was an independent predictor for metastasis in multivariate analysis (hazard ratio, 3.735; 95 % CI 0.629–22.174; P = 0.002). In conclusion, our study suggests that negative expression of metastin receptor in clear cell RCC is significantly related to metastasis.
Literatur
1.
Zurück zum Zitat West A, Vojta PJ, Welch DR, Weissman BE (1998) Chromosome localization and genomic structure of the KiSS-1 metastasis suppressor gene (KISS1). Genomics 54:145–148PubMedCrossRef West A, Vojta PJ, Welch DR, Weissman BE (1998) Chromosome localization and genomic structure of the KiSS-1 metastasis suppressor gene (KISS1). Genomics 54:145–148PubMedCrossRef
2.
Zurück zum Zitat Ohtaki T, Shintani Y, Honda S, Matsumoto H, Hori A, Kanehashi K, Terao Y, Kumano S, Takatsu Y, Masuda Y, Ishibashi Y, Watanabe T, Asada M, Yamada T, Suenaga M, Kitada C, Usuki S, Kurokawa T, Onda H, Nishimura O, Fujino M (2001) Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature 411:613–617PubMedCrossRef Ohtaki T, Shintani Y, Honda S, Matsumoto H, Hori A, Kanehashi K, Terao Y, Kumano S, Takatsu Y, Masuda Y, Ishibashi Y, Watanabe T, Asada M, Yamada T, Suenaga M, Kitada C, Usuki S, Kurokawa T, Onda H, Nishimura O, Fujino M (2001) Metastasis suppressor gene KiSS-1 encodes peptide ligand of a G-protein-coupled receptor. Nature 411:613–617PubMedCrossRef
3.
Zurück zum Zitat Shoji S, Tang XY, Sato H, Usui Y, Uchida T, Terachi T (2010) Metastin has potential as a suitable biomarker and novel effective therapy for cancer metastasis (Review). Oncol Lett 1:783–788PubMed Shoji S, Tang XY, Sato H, Usui Y, Uchida T, Terachi T (2010) Metastin has potential as a suitable biomarker and novel effective therapy for cancer metastasis (Review). Oncol Lett 1:783–788PubMed
4.
Zurück zum Zitat Roseweir AK, Millar RP (2009) The role of kisspeptin in the control of gonadotrophin secretion. Hum Reprod Update 15:203–212PubMedCrossRef Roseweir AK, Millar RP (2009) The role of kisspeptin in the control of gonadotrophin secretion. Hum Reprod Update 15:203–212PubMedCrossRef
5.
Zurück zum Zitat Shoji S, Tang XY, Umemura S, Itoh J, Takekoshi S, Shima M, Usui Y, Nagata Y, Uchida T, Osamura RY, Terachi T (2009) Metastin inhibits migration and invasion of renal cell carcinoma with overexpression of metastin receptor. Eur Urol 55:441–449PubMedCrossRef Shoji S, Tang XY, Umemura S, Itoh J, Takekoshi S, Shima M, Usui Y, Nagata Y, Uchida T, Osamura RY, Terachi T (2009) Metastin inhibits migration and invasion of renal cell carcinoma with overexpression of metastin receptor. Eur Urol 55:441–449PubMedCrossRef
6.
Zurück zum Zitat Chen Y, Yusenko MV, Kovacs G (2011) Lack of KiSS1R expression is associated with rapid progression of conventional renal cell carcinoma. J Pathol 223:46–53PubMedCrossRef Chen Y, Yusenko MV, Kovacs G (2011) Lack of KiSS1R expression is associated with rapid progression of conventional renal cell carcinoma. J Pathol 223:46–53PubMedCrossRef
7.
Zurück zum Zitat Wallen EM, Pruthi RS, Joyce GF, Wise M (2007) Urologic diseases in America project. Kidney cancer. J Urol 177:2006–2018PubMedCrossRef Wallen EM, Pruthi RS, Joyce GF, Wise M (2007) Urologic diseases in America project. Kidney cancer. J Urol 177:2006–2018PubMedCrossRef
8.
Zurück zum Zitat Levy DA, Slaton JW, Swanson DA, Dinney CP (1998) Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 159:1163–1167PubMedCrossRef Levy DA, Slaton JW, Swanson DA, Dinney CP (1998) Stage specific guidelines for surveillance after radical nephrectomy for local renal cell carcinoma. J Urol 159:1163–1167PubMedCrossRef
9.
Zurück zum Zitat Ljungberg B, Alamdari FI, Rasmuson T, Roos G (1999) Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int 84:405–411PubMedCrossRef Ljungberg B, Alamdari FI, Rasmuson T, Roos G (1999) Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int 84:405–411PubMedCrossRef
10.
Zurück zum Zitat Lam JS, Leppert JT, Figlin RA, Belldegrun AS (2005) Surveillance following radical or partial nephrectomy for renal cell carcinoma. Curr Urol Rep 6:7–18PubMedCrossRef Lam JS, Leppert JT, Figlin RA, Belldegrun AS (2005) Surveillance following radical or partial nephrectomy for renal cell carcinoma. Curr Urol Rep 6:7–18PubMedCrossRef
11.
Zurück zum Zitat Lau WK, Cheville JC, Blute ML, Weaver AL, Zincke H (2002) Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy. Urology 59:532–537PubMedCrossRef Lau WK, Cheville JC, Blute ML, Weaver AL, Zincke H (2002) Prognostic features of pathologic stage T1 renal cell carcinoma after radical nephrectomy. Urology 59:532–537PubMedCrossRef
12.
Zurück zum Zitat Adamy A, Chong KT, Chade D, Costaras J, Russo G, Kaag MG, Bernstein M, Motzer RJ, Russo P (2011) Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinoma. J Urol 185:433–438PubMedCrossRef Adamy A, Chong KT, Chade D, Costaras J, Russo G, Kaag MG, Bernstein M, Motzer RJ, Russo P (2011) Clinical characteristics and outcomes of patients with recurrence 5 years after nephrectomy for localized renal cell carcinoma. J Urol 185:433–438PubMedCrossRef
13.
Zurück zum Zitat Edge SB, Compton CC (2005) The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 173:918–921 Edge SB, Compton CC (2005) The American joint committee on cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 173:918–921
14.
Zurück zum Zitat Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol 5:649–655PubMedCrossRef Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP (1982) Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol 5:649–655PubMedCrossRef
15.
Zurück zum Zitat Uzzo RG, Novick AC (2003) Surveillance strategies following surgery for renal cell carcinoma. In: Belldegrum A, Ritchie AWS, Figlin RA, Oliver RTD, Vaughan ED Jr (eds) Renal and adrenal tumors: biology and management. Oxford University Press, Oxford, pp 324–330 Uzzo RG, Novick AC (2003) Surveillance strategies following surgery for renal cell carcinoma. In: Belldegrum A, Ritchie AWS, Figlin RA, Oliver RTD, Vaughan ED Jr (eds) Renal and adrenal tumors: biology and management. Oxford University Press, Oxford, pp 324–330
16.
Zurück zum Zitat Stephenson AJ, Chetner MP, Rourke K, Gleave ME, Signaevsky M, Palmer B, Kuan J, Brock GB, Tanguay S (2004) Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol 172:58–62PubMedCrossRef Stephenson AJ, Chetner MP, Rourke K, Gleave ME, Signaevsky M, Palmer B, Kuan J, Brock GB, Tanguay S (2004) Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy. J Urol 172:58–62PubMedCrossRef
17.
Zurück zum Zitat Eichelberg C, Junker K, Ljungberg B, Moch H (2009) Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol 55:851–863PubMedCrossRef Eichelberg C, Junker K, Ljungberg B, Moch H (2009) Diagnostic and prognostic molecular markers for renal cell carcinoma: a critical appraisal of the current state of research and clinical applicability. Eur Urol 55:851–863PubMedCrossRef
18.
Zurück zum Zitat Choisy-Rossi C, Yonish-Rouach E (1998) Apoptosis and the cell cycle: the p53 connection. Cell Death Differ 5:129–131PubMedCrossRef Choisy-Rossi C, Yonish-Rouach E (1998) Apoptosis and the cell cycle: the p53 connection. Cell Death Differ 5:129–131PubMedCrossRef
19.
Zurück zum Zitat Zigeuner R, Ratschek M, Rehak P, Schips L, Langner C (2004) Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. Urology 63:651–655PubMedCrossRef Zigeuner R, Ratschek M, Rehak P, Schips L, Langner C (2004) Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue. Urology 63:651–655PubMedCrossRef
20.
Zurück zum Zitat Cho DS, Joo HJ, Oh DK, Kang JH, Kim YS, Lee KB, Kim SJ (2005) Cyclooxygenase-2 and p53 expression as prognostic indicators in conventional renal cell carcinoma. Yonsei Med J 46:133–140PubMedCrossRef Cho DS, Joo HJ, Oh DK, Kang JH, Kim YS, Lee KB, Kim SJ (2005) Cyclooxygenase-2 and p53 expression as prognostic indicators in conventional renal cell carcinoma. Yonsei Med J 46:133–140PubMedCrossRef
21.
Zurück zum Zitat Kankuri M, Söderström KO, Pelliniemi TT, Vahlberg T, Pyrhönen S, Salminen E (2006) The association of immunoreactive p53 and Ki-67 with T-stage, grade, occurrence of metastases and survival in renal cell carcinoma. Anticancer Res 26:3825–3833PubMed Kankuri M, Söderström KO, Pelliniemi TT, Vahlberg T, Pyrhönen S, Salminen E (2006) The association of immunoreactive p53 and Ki-67 with T-stage, grade, occurrence of metastases and survival in renal cell carcinoma. Anticancer Res 26:3825–3833PubMed
22.
Zurück zum Zitat Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710–1715PubMed Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H (1984) Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133:1710–1715PubMed
23.
Zurück zum Zitat Kankuri-Tammilehto MK, Söderström KO, Pelliniemi TT, Vahlberg T, Pyrhönen SO, Salminen EK (2010) Prognostic evaluation of COX-2 expression in renal cell carcinoma. Anticancer Res 30:3023–3330PubMed Kankuri-Tammilehto MK, Söderström KO, Pelliniemi TT, Vahlberg T, Pyrhönen SO, Salminen EK (2010) Prognostic evaluation of COX-2 expression in renal cell carcinoma. Anticancer Res 30:3023–3330PubMed
24.
Zurück zum Zitat Taketo MM (1998) Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 90:1529–1536PubMedCrossRef Taketo MM (1998) Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J Natl Cancer Inst 90:1529–1536PubMedCrossRef
25.
Zurück zum Zitat Pruthi RS, Derksen E, Gaston K (2003) Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review. J Urol 169:2352–2359PubMedCrossRef Pruthi RS, Derksen E, Gaston K (2003) Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review. J Urol 169:2352–2359PubMedCrossRef
26.
Zurück zum Zitat Potter C, Harris AL (2004) Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 3:164–167PubMedCrossRef Potter C, Harris AL (2004) Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle 3:164–167PubMedCrossRef
27.
Zurück zum Zitat Sandlund J, Oosterwijk E, Grankvist K, Oosterwijk-Wakka J, Ljungberg B, Rasmuson T (2007) Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int 100:556–560PubMedCrossRef Sandlund J, Oosterwijk E, Grankvist K, Oosterwijk-Wakka J, Ljungberg B, Rasmuson T (2007) Prognostic impact of carbonic anhydrase IX expression in human renal cell carcinoma. BJU Int 100:556–560PubMedCrossRef
28.
Zurück zum Zitat Sakai I, Miyake H, Takenaka A, Fujisawa M (2009) Expression of potential molecular markers in renal cell carcinoma: impact on clinicopathological outcomes in patients undergoing radical nephrectomy. BJU Int 104:942–946PubMedCrossRef Sakai I, Miyake H, Takenaka A, Fujisawa M (2009) Expression of potential molecular markers in renal cell carcinoma: impact on clinicopathological outcomes in patients undergoing radical nephrectomy. BJU Int 104:942–946PubMedCrossRef
29.
Zurück zum Zitat Leroy X, Zerimech F, Zini L, Copin MC, Buisine MP, Gosselin B, Aubert JP, Porchet N (2002) MUC1 expression is correlated with nuclear grade and tumor progression in pT1 renal clear cell carcinoma. Am J Clin Pathol 118:47–51PubMedCrossRef Leroy X, Zerimech F, Zini L, Copin MC, Buisine MP, Gosselin B, Aubert JP, Porchet N (2002) MUC1 expression is correlated with nuclear grade and tumor progression in pT1 renal clear cell carcinoma. Am J Clin Pathol 118:47–51PubMedCrossRef
30.
Zurück zum Zitat O-Charoenrat P, Rhys-Evans P, Modjtahedi H, Court W, Box G, Eccles S (2000) Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion. Int J Cancer 86:307–317PubMedCrossRef O-Charoenrat P, Rhys-Evans P, Modjtahedi H, Court W, Box G, Eccles S (2000) Overexpression of epidermal growth factor receptor in human head and neck squamous carcinoma cell lines correlates with matrix metalloproteinase-9 expression and in vitro invasion. Int J Cancer 86:307–317PubMedCrossRef
31.
Zurück zum Zitat Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J (1995) Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 129:255–265PubMedCrossRef Wesseling J, van der Valk SW, Vos HL, Sonnenberg A, Hilkens J (1995) Episialin (MUC1) overexpression inhibits integrin-mediated cell adhesion to extracellular matrix components. J Cell Biol 129:255–265PubMedCrossRef
32.
Zurück zum Zitat Taylor-Papadimitriou J, Burchell J, Miles DW, Dalziel M (1999) MUC1 and cancer. Biochim Biophys Acta 1455:301–313PubMedCrossRef Taylor-Papadimitriou J, Burchell J, Miles DW, Dalziel M (1999) MUC1 and cancer. Biochim Biophys Acta 1455:301–313PubMedCrossRef
Metadaten
Titel
Value of metastin receptor immunohistochemistry in predicting metastasis after radical nephrectomy for pT1 clear cell renal cell carcinoma
verfasst von
Sunao Shoji
Mayura Nakano
Tetsuro Tomonaga
Hakushi Kim
Kazuya Hanai
Yukio Usui
Yoshihiro Nagata
Masaki Miyazawa
Haruhiro Sato
Xian Yang Tang
Yoshiyuki Robert Osamura
Toyoaki Uchida
Toshiro Terachi
Koichi Takeya
Publikationsdatum
01.06.2013
Verlag
Springer Netherlands
Erschienen in
Clinical & Experimental Metastasis / Ausgabe 5/2013
Print ISSN: 0262-0898
Elektronische ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-012-9564-3

Weitere Artikel der Ausgabe 5/2013

Clinical & Experimental Metastasis 5/2013 Zur Ausgabe

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.